Early Preservation of CXCR5 + PD-1 + Helper T Cells and B Cell Activation Predict the Breadth of Neutralizing Antibody Responses in Chronic HIV-1 Infection

Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infe...

Full description

Saved in:
Bibliographic Details
Published inJournal of virology Vol. 88; no. 22; pp. 13310 - 13321
Main Authors Cohen, Kristen, Altfeld, Marcus, Alter, Galit, Stamatatos, Leonidas
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.11.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5 + CD4 + T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5 + CD4 + T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5 + CD4 + T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5 + CD4 + T cells. Thus, the early preservation of CXCR5 + CD4 + T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection. IMPORTANCE Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5 + PD-1 + CD4 + T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5 + PD-1 + CD4 + T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.
AbstractList Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5+ CD4+ T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5+ CD4+ T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5+ CD4+ T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5+ CD4+ T cells. Thus, the early preservation of CXCR5+ CD4+ T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection. IMPORTANCE Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5+ PD-1+ CD4+ T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5+ PD-1+ CD4+ T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.
Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5 + CD4 + T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5 + CD4 + T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5 + CD4 + T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5 + CD4 + T cells. Thus, the early preservation of CXCR5 + CD4 + T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection. IMPORTANCE Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5 + PD-1 + CD4 + T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5 + PD-1 + CD4 + T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.
Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection.UNLABELLEDMuch is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection.Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.IMPORTANCEBroadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.
Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection. Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.
Author Stamatatos, Leonidas
Cohen, Kristen
Altfeld, Marcus
Alter, Galit
Author_xml – sequence: 1
  givenname: Kristen
  surname: Cohen
  fullname: Cohen, Kristen
  organization: Seattle Biomedical Research Institute, Seattle, Washington, USA, University of Washington, Department of Global Health, Seattle, Washington, USA
– sequence: 2
  givenname: Marcus
  surname: Altfeld
  fullname: Altfeld, Marcus
  organization: Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, Massachusetts, USA, Heinrich-Pette-Institut, Hamburg, Germany
– sequence: 3
  givenname: Galit
  surname: Alter
  fullname: Alter, Galit
  organization: Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, Massachusetts, USA
– sequence: 4
  givenname: Leonidas
  surname: Stamatatos
  fullname: Stamatatos, Leonidas
  organization: Seattle Biomedical Research Institute, Seattle, Washington, USA, University of Washington, Department of Global Health, Seattle, Washington, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25210168$$D View this record in MEDLINE/PubMed
BookMark eNqNUk1vEzEUtFARTQM3zshHJNhie-39uCClSyFBFVRVqXqzHPttY7Sxg-1USv9K_yxOGipAHDg9S54Zj9_METpw3gFCLyk5ppQ17z5fzY4Jo01VUP4EjShpm0IIyg_QiBDGClE214foKMbvhFDOK_4MHTLBKKFVM0L3pyoMG3weIEK4Vcl6h32Pu-vuQuA3-PxDQfOYwrCCgC9xB8MQsXIGn-zOeKKT3dOyhrE64bQAfBJAmbTYSn2BdQpqsHfW3eCJS3buzQZfQFx5FyFi63C3CN5Zjaezq_zczPWgt4rP0dNeDRFe7OcYfft4etlNi7Ovn2bd5KzQnNapUFrXUJq6bYguW9P0dQtczAWQVum6aRinylSCsNpQPq_7mhimmdagNBdVS8oxev-gu1rPl2A0uK1huQp2qcJGemXlnzfOLuSNv5Wc8ZaSMgu83gsE_2MNMcmljTqvRznw6yhpVYq87pzMf0CpYBWhmTJGr3639ejnV3gZ8PYBoIOPMUD_CKFEbrshczfkrhuS8gxnf8G1Tbvo8qfs8G_ST6Qyu08
CitedBy_id crossref_primary_10_3389_fimmu_2017_01338
crossref_primary_10_3389_fimmu_2023_1270908
crossref_primary_10_1097_QAI_0000000000001152
crossref_primary_10_3389_fimmu_2018_01901
crossref_primary_10_1093_femspd_ftz044
crossref_primary_10_1099_jgv_0_001016
crossref_primary_10_1111_imr_12501
crossref_primary_10_1186_s12977_018_0433_2
crossref_primary_10_1111_imr_12502
crossref_primary_10_2174_1570162X15666171124122044
crossref_primary_10_1111_imr_12504
crossref_primary_10_3389_fimmu_2022_959002
crossref_primary_10_1016_j_immuni_2015_12_011
crossref_primary_10_1038_s41467_022_29511_1
crossref_primary_10_1097_COH_0000000000000359
crossref_primary_10_1097_COH_0000000000000557
crossref_primary_10_1097_COH_0000000000000317
crossref_primary_10_1128_JVI_01685_18
crossref_primary_10_1016_S2055_6640_20_30497_0
crossref_primary_10_1097_COH_0000000000000552
crossref_primary_10_1097_COH_0000000000000554
crossref_primary_10_3389_fimmu_2017_00046
crossref_primary_10_3389_fimmu_2016_00501
crossref_primary_10_1016_j_jim_2020_112901
crossref_primary_10_1016_j_celrep_2016_10_085
crossref_primary_10_1128_JVI_00659_18
crossref_primary_10_7448_IAS_19_1_21136
crossref_primary_10_3389_fimmu_2018_01975
crossref_primary_10_3389_fimmu_2020_608003
crossref_primary_10_3389_fimmu_2022_837921
crossref_primary_10_1016_j_virol_2020_03_003
crossref_primary_10_1371_journal_pone_0175570
crossref_primary_10_1016_j_ebiom_2020_102727
crossref_primary_10_3390_v10060336
crossref_primary_10_3389_fimmu_2017_01380
crossref_primary_10_3389_fimmu_2017_01104
crossref_primary_10_1128_JVI_00049_16
crossref_primary_10_2222_jsv_69_129
crossref_primary_10_3389_fendo_2019_00471
crossref_primary_10_1186_s12977_018_0443_0
crossref_primary_10_1016_j_jiph_2018_01_005
crossref_primary_10_1371_journal_ppat_1006825
crossref_primary_10_1371_journal_ppat_1006987
crossref_primary_10_1177_1179555717695548
crossref_primary_10_3389_fimmu_2017_00780
crossref_primary_10_1097_COH_0000000000000893
crossref_primary_10_1080_21645515_2020_1754701
crossref_primary_10_1073_pnas_1520112113
crossref_primary_10_3389_fped_2021_618191
crossref_primary_10_1038_srep29556
crossref_primary_10_1146_annurev_med_091014_090749
crossref_primary_10_3389_fimmu_2020_00252
crossref_primary_10_3389_fimmu_2019_01497
crossref_primary_10_4049_jimmunol_2200145
crossref_primary_10_3389_fimmu_2019_02941
crossref_primary_10_1016_j_tim_2014_12_007
crossref_primary_10_1111_imr_12512
crossref_primary_10_1371_journal_ppat_1005369
crossref_primary_10_3390_ijms19041241
crossref_primary_10_1128_mBio_00317_18
crossref_primary_10_1002_jmv_29381
crossref_primary_10_1111_sji_12868
crossref_primary_10_1126_sciimmunol_aag0851
crossref_primary_10_3389_fimmu_2021_638872
crossref_primary_10_1128_JVI_02278_15
Cites_doi 10.1016/j.cell.2013.03.018
10.1128/JVI.01272-09
10.1586/14760584.5.4.579
10.1128/JVI.73.5.4009-4018.1999
10.1126/science.1207532
10.1084/jem.193.12.1373
10.1097/01.aids.0000432455.06476.bc
10.1089/jir.2005.25.702
10.4049/jimmunol.1002828
10.1002/eji.1830220233
10.1128/JVI.02497-12
10.1128/JVI.01762-08
10.1038/nature12746
10.1016/j.immuni.2013.02.020
10.1038/nm.3109
10.1016/j.cell.2010.10.032
10.1128/JVI.00878-13
10.1146/annurev-immunol-030409-101256
10.1093/intimm/dxt058
10.1084/jem.20091706
10.1084/jem.193.3.297
10.1084/jem.192.11.1545
10.1182/blood-2005-07-2955
10.1128/JVI.01482-09
10.4049/jimmunol.177.7.4927
10.1182/blood-2008-02-140426
10.1172/JCI64314
10.1038/nature12744
10.1128/JVI.01583-08
10.1128/JVI.01679-09
10.1084/jem.20102477
10.1371/journal.ppat.1000433
10.1016/j.chom.2012.09.008
10.1111/j.1365-2249.2011.04465.x
10.1371/journal.ppat.1003853
10.1126/science.1176676
10.1126/science.2658060
10.1084/jem.192.11.1553
10.1038/72309
10.1128/JVI.00598-07
10.1016/j.coi.2012.04.006
10.1146/annurev-immunol-031210-101400
10.1016/j.immuni.2013.08.031
10.1073/pnas.1530509100
10.1128/JVI.02036-08
10.1038/nm1244
10.1128/jvi.68.7.4650-4655.1994
10.1128/JVI.00110-09
10.1371/journal.ppat.1001251
10.1073/pnas.1103012108
10.1021/bi00895a027
10.1126/science.1207227
10.1002/art.25032
10.1097/QAD.0b013e32833243e7
10.1038/nature11604
10.1073/pnas.1214785109
10.1038/nature12053
10.1126/science.8493576
10.1016/S0065-2776(08)60414-9
10.1016/j.immuni.2009.07.002
10.4049/jimmunol.1002955
10.1016/j.immuni.2010.12.012
10.1016/j.immuni.2012.08.012
10.1172/JCI63039
10.1128/JVI.75.17.8340-8347.2001
10.1016/j.virol.2009.10.044
10.1084/jem.20121932
ContentType Journal Article
Copyright Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology
Copyright_xml – notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved.
– notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7T5
7U9
H94
5PM
DOI 10.1128/JVI.02186-14
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Immunology Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
DatabaseTitleList AIDS and Cancer Research Abstracts

MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1098-5514
EndPage 13321
ExternalDocumentID PMC4249103
25210168
10_1128_JVI_02186_14
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: P01 AI078064
– fundername: NIAID NIH HHS
  grantid: R01 AI081625
– fundername: NIH HHS
  grantid: P51 OD010425
– fundername: PHS HHS
  grantid: NIAID R01AI081625
GroupedDBID ---
-~X
0R~
18M
29L
2WC
39C
4.4
53G
5GY
5RE
5VS
85S
AAFWJ
AAGFI
AAYXX
ABPPZ
ACGFO
ACNCT
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CITATION
CS3
DIK
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
N9A
O9-
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
W2D
W8F
WH7
WOQ
YQT
~02
~KM
.55
.GJ
3O-
41~
6TJ
AAYJJ
ADXHL
AFFNX
AI.
C1A
CGR
CUY
CVF
D0S
ECM
EIF
MVM
NPM
OHT
VH1
X7M
Y6R
ZGI
ZXP
7X8
7T5
7U9
H94
5PM
ID FETCH-LOGICAL-c417t-acc7e3d7980c39d8f79e45b5e09ac788241ad65027d14b7f70d2c2cceac456903
ISSN 0022-538X
1098-5514
IngestDate Thu Aug 21 18:10:22 EDT 2025
Fri Jul 11 08:08:22 EDT 2025
Fri Jul 11 12:05:57 EDT 2025
Mon Jul 21 05:36:48 EDT 2025
Tue Jul 01 01:02:34 EDT 2025
Thu Apr 24 23:11:56 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 22
Language English
License Copyright © 2014, American Society for Microbiology. All Rights Reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c417t-acc7e3d7980c39d8f79e45b5e09ac788241ad65027d14b7f70d2c2cceac456903
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://jvi.asm.org/content/jvi/88/22/13310.full.pdf
PMID 25210168
PQID 1615260116
PQPubID 23479
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4249103
proquest_miscellaneous_1635016098
proquest_miscellaneous_1615260116
pubmed_primary_25210168
crossref_primary_10_1128_JVI_02186_14
crossref_citationtrail_10_1128_JVI_02186_14
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-11-01
PublicationDateYYYYMMDD 2014-11-01
PublicationDate_xml – month: 11
  year: 2014
  text: 2014-11-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Journal of virology
PublicationTitleAlternate J Virol
PublicationYear 2014
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_3_50_2
e_1_3_3_16_2
e_1_3_3_18_2
e_1_3_3_39_2
e_1_3_3_12_2
e_1_3_3_37_2
e_1_3_3_58_2
e_1_3_3_14_2
e_1_3_3_35_2
e_1_3_3_56_2
e_1_3_3_33_2
e_1_3_3_54_2
e_1_3_3_10_2
e_1_3_3_31_2
e_1_3_3_52_2
e_1_3_3_40_2
e_1_3_3_61_2
e_1_3_3_5_2
e_1_3_3_7_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_29_2
e_1_3_3_23_2
e_1_3_3_48_2
e_1_3_3_69_2
e_1_3_3_25_2
e_1_3_3_46_2
e_1_3_3_67_2
e_1_3_3_44_2
e_1_3_3_65_2
e_1_3_3_3_2
e_1_3_3_21_2
e_1_3_3_42_2
e_1_3_3_63_2
e_1_3_3_51_2
e_1_3_3_17_2
e_1_3_3_19_2
e_1_3_3_38_2
e_1_3_3_13_2
e_1_3_3_36_2
e_1_3_3_59_2
e_1_3_3_15_2
e_1_3_3_34_2
e_1_3_3_57_2
e_1_3_3_32_2
e_1_3_3_55_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_53_2
e_1_3_3_62_2
e_1_3_3_60_2
e_1_3_3_6_2
e_1_3_3_8_2
e_1_3_3_28_2
e_1_3_3_49_2
e_1_3_3_24_2
e_1_3_3_47_2
e_1_3_3_26_2
e_1_3_3_45_2
e_1_3_3_68_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_43_2
e_1_3_3_66_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_41_2
e_1_3_3_64_2
10196297 - J Virol. 1999 May;73(5):4009-18
14214095 - Biochemistry. 1964 Jul;3:996-1008
23720719 - J Virol. 2013 Aug;87(15):8798-804
19906907 - J Virol. 2010 Feb;84(3):1302-13
19906933 - J Virol. 2010 Jan;84(2):953-63
16982935 - J Immunol. 2006 Oct 1;177(7):4927-32
23475201 - Nat Med. 2013 Apr;19(4):494-9
11157050 - J Exp Med. 2001 Feb 5;193(3):297-305
21690411 - Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6
23103874 - Nature. 2012 Dec 6;492(7427):118-22
19439467 - J Virol. 2009 Jul;83(14):7337-48
23540694 - Cell. 2013 Mar 28;153(1):126-38
23552890 - Nature. 2013 Apr 25;496(7446):469-76
23084910 - Cell Host Microbe. 2012 Oct 18;12(4):396-407
19631565 - Immunity. 2009 Sep 18;31(3):457-68
23100539 - Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5
11104798 - J Exp Med. 2000 Dec 4;192(11):1553-62
21764753 - Science. 2011 Sep 16;333(6049):1633-7
18815292 - J Virol. 2008 Dec;82(23):11651-68
24172905 - Nature. 2013 Nov 14;503(7475):224-8
4900673 - Adv Immunol. 1969;10:1-50
8493576 - Science. 1993 May 28;260(5112):1323-7
23254284 - J Exp Med. 2013 Jan 14;210(1):143-56
18922865 - J Virol. 2009 Jan;83(1):188-99
18987148 - J Virol. 2009 Jan;83(2):757-69
21215658 - Immunity. 2011 Jan 28;34(1):108-21
17567707 - J Virol. 2007 Aug;81(16):8793-808
21985363 - Clin Exp Immunol. 2011 Nov;166(2):171-83
11483779 - J Virol. 2001 Sep;75(17):8340-7
21835983 - Science. 2011 Sep 16;333(6049):1593-602
1537385 - Eur J Immunol. 1992 Feb;22(2):511-7
19770692 - AIDS. 2009 Nov 27;23(18):2405-14
10655110 - Nat Med. 2000 Feb;6(2):200-6
19923174 - J Virol. 2010 Feb;84(3):1631-6
11104797 - J Exp Med. 2000 Dec 4;192(11):1545-52
8207839 - J Virol. 1994 Jul;68(7):4650-5
21576382 - J Exp Med. 2011 Jun 6;208(6):1243-52
22595693 - Curr Opin Immunol. 2012 Jun;24(3):316-23
19436712 - PLoS Pathog. 2009 May;5(5):e1000433
21249232 - PLoS Pathog. 2011;7(1):e1001251
24497824 - PLoS Pathog. 2014 Jan;10(1):e1003853
18780835 - Blood. 2008 Dec 1;112(12):4401-10
20192810 - Annu Rev Immunol. 2010;28:413-44
21471443 - J Immunol. 2011 May 15;186(10):5556-68
22922258 - J Clin Invest. 2012 Sep;122(9):3281-94
22999947 - Immunity. 2012 Sep 21;37(3):412-25
19922969 - Virology. 2010 Jan 20;396(2):339-48
23325697 - J Virol. 2013 Apr;87(7):3760-73
12883005 - Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
16989638 - Expert Rev Vaccines. 2006 Aug;5(4):579-95
16318584 - J Interferon Cytokine Res. 2005 Nov;25(11):702-6
22922259 - J Clin Invest. 2012 Sep;122(9):3271-80
24291746 - Int Immunol. 2014 Mar;26(3):183-92
24172896 - Nature. 2013 Nov 14;503(7475):277-80
21270407 - J Immunol. 2011 Mar 1;186(5):2889-96
15880120 - Nat Med. 2005 Jun;11(6):615-22
16384931 - Blood. 2006 Apr 15;107(8):3045-52
20039395 - Arthritis Rheum. 2010 Jan;62(1):234-44
21074050 - Cell. 2010 Nov 12;143(4):592-605
2658060 - Science. 1989 Jun 9;244(4909):1152-7
20048285 - J Exp Med. 2010 Jan 18;207(1):155-71
11413192 - J Exp Med. 2001 Jun 18;193(12):1373-81
21314428 - Annu Rev Immunol. 2011;29:621-63
19628815 - Science. 2009 Aug 21;325(5943):1001-5
24096630 - AIDS. 2013 Oct 23;27(16):2505-17
23583644 - Immunity. 2013 Apr 18;38(4):805-17
24035365 - Immunity. 2013 Oct 17;39(4):758-69
References_xml – ident: e_1_3_3_67_2
  doi: 10.1016/j.cell.2013.03.018
– ident: e_1_3_3_12_2
  doi: 10.1128/JVI.01272-09
– ident: e_1_3_3_27_2
  doi: 10.1586/14760584.5.4.579
– ident: e_1_3_3_14_2
  doi: 10.1128/JVI.73.5.4009-4018.1999
– ident: e_1_3_3_65_2
  doi: 10.1126/science.1207532
– ident: e_1_3_3_38_2
  doi: 10.1084/jem.193.12.1373
– ident: e_1_3_3_52_2
  doi: 10.1097/01.aids.0000432455.06476.bc
– ident: e_1_3_3_53_2
  doi: 10.1089/jir.2005.25.702
– ident: e_1_3_3_40_2
  doi: 10.4049/jimmunol.1002828
– ident: e_1_3_3_31_2
  doi: 10.1002/eji.1830220233
– ident: e_1_3_3_46_2
  doi: 10.1128/JVI.02497-12
– ident: e_1_3_3_2_2
  doi: 10.1128/JVI.01762-08
– ident: e_1_3_3_19_2
  doi: 10.1038/nature12746
– ident: e_1_3_3_42_2
  doi: 10.1016/j.immuni.2013.02.020
– ident: e_1_3_3_48_2
  doi: 10.1038/nm.3109
– ident: e_1_3_3_64_2
  doi: 10.1016/j.cell.2010.10.032
– ident: e_1_3_3_18_2
  doi: 10.1128/JVI.00878-13
– ident: e_1_3_3_24_2
  doi: 10.1146/annurev-immunol-030409-101256
– ident: e_1_3_3_58_2
  doi: 10.1093/intimm/dxt058
– ident: e_1_3_3_60_2
  doi: 10.1084/jem.20091706
– ident: e_1_3_3_62_2
  doi: 10.1084/jem.193.3.297
– ident: e_1_3_3_35_2
  doi: 10.1084/jem.192.11.1545
– ident: e_1_3_3_56_2
  doi: 10.1182/blood-2005-07-2955
– ident: e_1_3_3_3_2
  doi: 10.1128/JVI.01482-09
– ident: e_1_3_3_57_2
  doi: 10.4049/jimmunol.177.7.4927
– ident: e_1_3_3_54_2
  doi: 10.1182/blood-2008-02-140426
– ident: e_1_3_3_51_2
  doi: 10.1172/JCI64314
– ident: e_1_3_3_17_2
  doi: 10.1038/nature12744
– ident: e_1_3_3_55_2
  doi: 10.1128/JVI.01583-08
– ident: e_1_3_3_25_2
  doi: 10.1128/JVI.01679-09
– ident: e_1_3_3_63_2
  doi: 10.1084/jem.20102477
– ident: e_1_3_3_11_2
  doi: 10.1371/journal.ppat.1000433
– ident: e_1_3_3_23_2
  doi: 10.1016/j.chom.2012.09.008
– ident: e_1_3_3_61_2
  doi: 10.1111/j.1365-2249.2011.04465.x
– ident: e_1_3_3_49_2
  doi: 10.1371/journal.ppat.1003853
– ident: e_1_3_3_37_2
  doi: 10.1126/science.1176676
– ident: e_1_3_3_29_2
  doi: 10.1126/science.2658060
– ident: e_1_3_3_36_2
  doi: 10.1084/jem.192.11.1553
– ident: e_1_3_3_9_2
  doi: 10.1038/72309
– ident: e_1_3_3_22_2
  doi: 10.1128/JVI.00598-07
– ident: e_1_3_3_26_2
  doi: 10.1016/j.coi.2012.04.006
– ident: e_1_3_3_33_2
  doi: 10.1146/annurev-immunol-031210-101400
– ident: e_1_3_3_43_2
  doi: 10.1016/j.immuni.2013.08.031
– ident: e_1_3_3_50_2
  doi: 10.1073/pnas.1530509100
– ident: e_1_3_3_5_2
  doi: 10.1128/JVI.02036-08
– ident: e_1_3_3_21_2
  doi: 10.1038/nm1244
– ident: e_1_3_3_59_2
  doi: 10.1128/jvi.68.7.4650-4655.1994
– ident: e_1_3_3_6_2
  doi: 10.1128/JVI.00110-09
– ident: e_1_3_3_8_2
  doi: 10.1371/journal.ppat.1001251
– ident: e_1_3_3_10_2
  doi: 10.1073/pnas.1103012108
– ident: e_1_3_3_28_2
  doi: 10.1021/bi00895a027
– ident: e_1_3_3_66_2
  doi: 10.1126/science.1207227
– ident: e_1_3_3_44_2
  doi: 10.1002/art.25032
– ident: e_1_3_3_7_2
  doi: 10.1097/QAD.0b013e32833243e7
– ident: e_1_3_3_20_2
  doi: 10.1038/nature11604
– ident: e_1_3_3_15_2
  doi: 10.1073/pnas.1214785109
– ident: e_1_3_3_32_2
  doi: 10.1038/nature12053
– ident: e_1_3_3_13_2
  doi: 10.1126/science.8493576
– ident: e_1_3_3_30_2
  doi: 10.1016/S0065-2776(08)60414-9
– ident: e_1_3_3_34_2
  doi: 10.1016/j.immuni.2009.07.002
– ident: e_1_3_3_41_2
  doi: 10.4049/jimmunol.1002955
– ident: e_1_3_3_39_2
  doi: 10.1016/j.immuni.2010.12.012
– ident: e_1_3_3_68_2
  doi: 10.1016/j.immuni.2012.08.012
– ident: e_1_3_3_45_2
  doi: 10.1172/JCI63039
– ident: e_1_3_3_69_2
  doi: 10.1038/nature12053
– ident: e_1_3_3_16_2
  doi: 10.1128/JVI.75.17.8340-8347.2001
– ident: e_1_3_3_4_2
  doi: 10.1016/j.virol.2009.10.044
– ident: e_1_3_3_47_2
  doi: 10.1084/jem.20121932
– reference: 8207839 - J Virol. 1994 Jul;68(7):4650-5
– reference: 21270407 - J Immunol. 2011 Mar 1;186(5):2889-96
– reference: 19906907 - J Virol. 2010 Feb;84(3):1302-13
– reference: 23100539 - Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5
– reference: 24497824 - PLoS Pathog. 2014 Jan;10(1):e1003853
– reference: 23552890 - Nature. 2013 Apr 25;496(7446):469-76
– reference: 20192810 - Annu Rev Immunol. 2010;28:413-44
– reference: 20039395 - Arthritis Rheum. 2010 Jan;62(1):234-44
– reference: 11157050 - J Exp Med. 2001 Feb 5;193(3):297-305
– reference: 21690411 - Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6
– reference: 22595693 - Curr Opin Immunol. 2012 Jun;24(3):316-23
– reference: 8493576 - Science. 1993 May 28;260(5112):1323-7
– reference: 24035365 - Immunity. 2013 Oct 17;39(4):758-69
– reference: 10655110 - Nat Med. 2000 Feb;6(2):200-6
– reference: 18987148 - J Virol. 2009 Jan;83(2):757-69
– reference: 20048285 - J Exp Med. 2010 Jan 18;207(1):155-71
– reference: 18922865 - J Virol. 2009 Jan;83(1):188-99
– reference: 21471443 - J Immunol. 2011 May 15;186(10):5556-68
– reference: 15880120 - Nat Med. 2005 Jun;11(6):615-22
– reference: 23720719 - J Virol. 2013 Aug;87(15):8798-804
– reference: 24096630 - AIDS. 2013 Oct 23;27(16):2505-17
– reference: 23325697 - J Virol. 2013 Apr;87(7):3760-73
– reference: 24172905 - Nature. 2013 Nov 14;503(7475):224-8
– reference: 10196297 - J Virol. 1999 May;73(5):4009-18
– reference: 21835983 - Science. 2011 Sep 16;333(6049):1593-602
– reference: 11104798 - J Exp Med. 2000 Dec 4;192(11):1553-62
– reference: 14214095 - Biochemistry. 1964 Jul;3:996-1008
– reference: 16318584 - J Interferon Cytokine Res. 2005 Nov;25(11):702-6
– reference: 16982935 - J Immunol. 2006 Oct 1;177(7):4927-32
– reference: 21215658 - Immunity. 2011 Jan 28;34(1):108-21
– reference: 21576382 - J Exp Med. 2011 Jun 6;208(6):1243-52
– reference: 21074050 - Cell. 2010 Nov 12;143(4):592-605
– reference: 4900673 - Adv Immunol. 1969;10:1-50
– reference: 18815292 - J Virol. 2008 Dec;82(23):11651-68
– reference: 19628815 - Science. 2009 Aug 21;325(5943):1001-5
– reference: 16384931 - Blood. 2006 Apr 15;107(8):3045-52
– reference: 19436712 - PLoS Pathog. 2009 May;5(5):e1000433
– reference: 23540694 - Cell. 2013 Mar 28;153(1):126-38
– reference: 23254284 - J Exp Med. 2013 Jan 14;210(1):143-56
– reference: 19770692 - AIDS. 2009 Nov 27;23(18):2405-14
– reference: 19439467 - J Virol. 2009 Jul;83(14):7337-48
– reference: 11413192 - J Exp Med. 2001 Jun 18;193(12):1373-81
– reference: 18780835 - Blood. 2008 Dec 1;112(12):4401-10
– reference: 21764753 - Science. 2011 Sep 16;333(6049):1633-7
– reference: 23084910 - Cell Host Microbe. 2012 Oct 18;12(4):396-407
– reference: 22999947 - Immunity. 2012 Sep 21;37(3):412-25
– reference: 11483779 - J Virol. 2001 Sep;75(17):8340-7
– reference: 2658060 - Science. 1989 Jun 9;244(4909):1152-7
– reference: 22922259 - J Clin Invest. 2012 Sep;122(9):3271-80
– reference: 24291746 - Int Immunol. 2014 Mar;26(3):183-92
– reference: 17567707 - J Virol. 2007 Aug;81(16):8793-808
– reference: 21985363 - Clin Exp Immunol. 2011 Nov;166(2):171-83
– reference: 24172896 - Nature. 2013 Nov 14;503(7475):277-80
– reference: 21314428 - Annu Rev Immunol. 2011;29:621-63
– reference: 19906933 - J Virol. 2010 Jan;84(2):953-63
– reference: 23475201 - Nat Med. 2013 Apr;19(4):494-9
– reference: 1537385 - Eur J Immunol. 1992 Feb;22(2):511-7
– reference: 23583644 - Immunity. 2013 Apr 18;38(4):805-17
– reference: 19923174 - J Virol. 2010 Feb;84(3):1631-6
– reference: 19922969 - Virology. 2010 Jan 20;396(2):339-48
– reference: 21249232 - PLoS Pathog. 2011;7(1):e1001251
– reference: 12883005 - Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
– reference: 16989638 - Expert Rev Vaccines. 2006 Aug;5(4):579-95
– reference: 23103874 - Nature. 2012 Dec 6;492(7427):118-22
– reference: 22922258 - J Clin Invest. 2012 Sep;122(9):3281-94
– reference: 19631565 - Immunity. 2009 Sep 18;31(3):457-68
– reference: 11104797 - J Exp Med. 2000 Dec 4;192(11):1545-52
SSID ssj0014464
Score 2.403284
Snippet Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 13310
SubjectTerms Antibodies, Neutralizing - blood
B-Lymphocytes - immunology
Cellular Response to Infection
Cohort Studies
HIV Antibodies - blood
HIV Infections - immunology
HIV-1 - immunology
Human immunodeficiency virus 1
Humans
Longitudinal Studies
Programmed Cell Death 1 Receptor - analysis
Receptors, CXCR5 - analysis
T-Lymphocyte Subsets - chemistry
T-Lymphocyte Subsets - immunology
T-Lymphocytes, Helper-Inducer - chemistry
T-Lymphocytes, Helper-Inducer - immunology
Title Early Preservation of CXCR5 + PD-1 + Helper T Cells and B Cell Activation Predict the Breadth of Neutralizing Antibody Responses in Chronic HIV-1 Infection
URI https://www.ncbi.nlm.nih.gov/pubmed/25210168
https://www.proquest.com/docview/1615260116
https://www.proquest.com/docview/1635016098
https://pubmed.ncbi.nlm.nih.gov/PMC4249103
Volume 88
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWMFAV6KbrX3cACzUlQKlGSJR9td3GCuggKJ_BNEBchAhzZSORD8yf9zX5BZ0hKppumaHORZYkmbc_jcN5oZkjIuwgWOS5j6QcZT_y45NwvsrD0UxkVPE1UqALMRp59HUxP4qNFsuj1fjpRS5uGH4irP-aV3EaqcA3kilmy_yHZrlO4AOcgXziChOH4TzI21YkxiqJ1reroisXkW7LPxt7xBz_EV1ha1urCm3sTtVyamsxjfe6NRLu7GfYiK9HYgAGQfHOmvQlqo30hV9p9UjcVX0k023VkrQ7m8mx9XW96eOqHoHBMdFd9g9mLeXWuJ7_LD9HqZpuYNlo2pd09ewaTcXPp3DAw-4wUovMQNQXY3kVjoga_KPhGstjxaYSxTe7rUNg-rHIjV2fVtjKVq9GRTEd6e2JYz4wSxxqpaAm6Wj7LHDSbVGirs4Gl28ha1b43SdvXVxeGGRNHp4cHeisv34zgAG19rpHGwCYCUzrbrrFd5OPxbBID4w2xQO0dBtSGtR4m--QL6HncVrjH39Uma7DsvTswFrG2o-xaVNdo0u_Rvo75NH9A7lsA0JEB8UPSU_UjctfshPr9MfmhoUxdKNNVSTWUPYpA9qiBMZ1TDWMKMKZjfU63MKYWxhRgTC2MsSMXxrSFMe1gTKuaWhhTDWPawfgJOfn0cT6Z-nbXEF_EYdr4hRCpimQ6zAIRDWVWpkMVJzxRwbAQKRDKOCwk8BKWyjDmaZkGkgkmBFggQCaGQfSU7NWrWj0nVIqMlaIoQgFgSuSAKyw9FUdKBYwDNekTr_3nc2FL6uPOLstcU2uW5SCyXIsMKHaf7Het16aUzA3t3rZCzEHX4wO8olarzWWO7AxLAIaDv7XBUIEBTIE-eWYE343WIqZP0h1IdA2w1vzunbo60zXnLWhf3PqTL8k9mOmZiQR7Rfaai416DfZ8w9_oCfALY-b4Kw
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+Preservation+of+CXCR5%2B+PD-1%2B+Helper+T+Cells+and+B+Cell+Activation+Predict+the+Breadth+of+Neutralizing+Antibody+Responses+in+Chronic+HIV-1+Infection&rft.jtitle=Journal+of+virology&rft.au=Cohen%2C+Kristen&rft.au=Altfeld%2C+Marcus&rft.au=Alter%2C+Galit&rft.au=Stamatatos%2C+Leonidas&rft.date=2014-11-01&rft.pub=American+Society+for+Microbiology&rft.issn=0022-538X&rft.eissn=1098-5514&rft.volume=88&rft.issue=22&rft.spage=13310&rft.epage=13321&rft_id=info:doi/10.1128%2FJVI.02186-14&rft_id=info%3Apmid%2F25210168&rft.externalDocID=PMC4249103
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon